ELTS Score: EUTOS Long-Term Survival score for CML. Specifically designed to predict CML-specific death in patients receiving Tyrosine Kinase Inhibitors (TKIs).
Guidelines & Evidence
Clinical Details
Section 1
When to Use
When to Use
Risk stratification of patients with Chronic Myeloid Leukemia (CML) at the time of diagnosis (Chronic Phase).
Predicting the probability of CML-related death in the era of Tyrosine Kinase Inhibitors (TKIs).
Differentiating risk groups to guide TKI selection (standard vs. 2nd-generation).
Patient Population
Adult patients with newly diagnosed Ph-positive CML in Chronic Phase starting TKI therapy.
When Not to Rely on This Score Alone
CML in Accelerated Phase or Blast Crisis — requires immediate aggressive therapy regardless of score.
Pediatric CML — while Sokal and ELTS are used, their predictive value is less established in children.
To monitor response to therapy — use BCR::ABL1 transcript levels (IS) for molecular monitoring.
The Sokal Score was developed in the 1980s (chemotherapy/interferon era). It tends to overestimate CML-related death in the era of modern TKIs like Imatinib and Nilotinib. The ELTS score was specifically designed to predict CML-specific mortality and identifies a larger proportion of low-risk patients with excellent outcomes.
Section 4
Evidence Appraisal
Primary Score
Prognostic score for survival of patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors.
Pfirrmann M et al. • Journal of the National Cancer Institute. 2016;108(1):djv301. n=2,205 patients validated.
Developed by the European Treatment and Outcome Study (EUTOS) group. It incorporates spleen size, age, blasts, and platelets into a non-linear model to reflect the modern natural history of TKI-treated CML.